Phase I/II Study of Recombinant Human Interferon-gamma (rIFN-gamma) in HIV-Infected Children

Inclusion Criteria Concurrent Medication: Required: AZT or ddI therapy. PCP prophylaxis. Allowed: Antipyretics. Antiemetics. Antihistamines. Decongestants. Skin creams and lotions. Immunizations according to current recommendations. Patients must have: Class P-2 symptomatic HIV infection. Ongoing AZT or ddI therapy of 6 months or longer duration. Exclusion Criteria Concurrent Medication: Excluded: Antiretroviral therapy other than AZT or ddI. Chemotherapy for active malignancy. Amphotericin B for systemic fungal infections. Patients with the following prior conditions are excluded: History of congestive heart failure or arrhythmias. History of congenital heart disease. History of seizure disorder requiring anticonvulsant medication. (NOTE: History of uncomplicated febrile seizures does not exclude.) Prior Medication: Excluded within 8 weeks prior to study entry: Immunomodulators other than IVIG. Prior Treatment: Excluded: Red blood cell transfusion within 4 weeks prior to study entry. Required: Ongoing AZT or ddI therapy of 6 weeks or longer duration. Ongoing PCP prophylaxis for more than 6 weeks duration. Ongoing alcohol or drug use.